Invitae Corp
invitae.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 8, 2023. Its latest SEC filing is a SCHEDULE 13G/A from Jan 10, 2025.
10-Q for Q3 FY2023, filed Nov 8, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Provides precision oncology testing, other genetic tests, and digital health and health data services to patients, healthcare providers, and biopharma partners.
10-K for FY2022, filed Feb 28, 2023
How Did They Make Money?
Patients or insurers and institutional customers pay for diagnostic tests and precision oncology products; biopharma partners pay for development and data services. Some development services are billed in advance, including at milestone start, while test collection timing varies by customer and payer.
10-K for FY2022, filed Feb 28, 2023
-
10-K for FY2022, filed Feb 28, 2023
FY2022 revenue by product or service ↗
$516.3M
-
10-K for FY2022, filed Mar 1, 2023
$516.3M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Oncology
Sold outright
|
60% |
Oncology, FY2022
$308.5M Sources
|
Sold outright |
|
Women's health
Sold outright
10-K for FY2022, filed Feb 28, 2023 |
19% |
Women's health, FY2022
$95.8M Sources
|
Sold outright |
|
Rare diseases
Sold outright
10-K for FY2022, filed Feb 28, 2023 |
13% |
Rare diseases, FY2022
$66M Sources
|
Sold outright |
|
Data/services
|
8.9% |
Data/services, FY2022
$46M Sources
|
Who Were Their Customers?
Patients can pay directly or through insurance for diagnostic testing; institutional customers include hospitals, clinics, medical centers and biopharma partners. Biopharma partners also buy development, collaboration and genome-network services.
How Were They Changing?
10-Q for Q3 FY2023, filed Nov 8, 2023
Open tableView ↗
-
Aug 8, 2024
Invitae completed an asset sale and its bankruptcy plan took effect
The plan provides for distributing sale proceeds and winding down the remaining estates; common stock was cancelled without consideration.
Sources
8-K, filed Aug 8, 2024
The Plan authorized, among other things, the (i) distribution of proceeds and (ii) winding down of the remainder of the Company Parties’…View ↗
-
May 2, 2024
Invitae agreed to sell its business to a Labcorp affiliate
The purchaser agreed to assume certain liabilities.
Sources
8-K, filed May 2, 2024
On May 1, 2024, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Laboratory Corporation of…View ↗
-
Feb 14, 2024
Invitae filed for Chapter 11 and began a court-supervised sale process
The company said it would continue operating during the proceedings.
Sources
8-K, filed Feb 14, 2024
On February 13, 2024 (the “Petition Date”), Invitae Corporation (the “Company”) and certain of its direct and indirect subsidiaries…View ↗
Grew. Revenue grew 3.5x in 4 years, from $147.7M in FY2018 to $516.3M in FY2022, about 37% a year.
Who Did They Compete With?
Competes with Ambry Genetics, Athena Diagnostics, Blueprint Genetics, Baylor-Miraca Genetics Laboratories, Caris Life Sciences, Centogene, Color Health, Connective Tissue Gene Test, Cooper Surgical, Emory Genetics Laboratory, Exact Sciences, Foundation Medicine, Fulgent Genetics, GeneDx Holdings, Guardant Health, Integrated Genetics, Sequenom, Correlagen Diagnositcs, MNG Laboratories, and Myriad Genetics
10-K for FY2022, filed Feb 28, 2023Our competitors include companies that offer molecular genetic testing and consulting services, including specialty and reference…View ↗
Loading...
